Anti-proliferative and anti-apoptotic potential effects of epigallocatechin-3-gallate and/or metformin on hepatocellular carcinoma cells: in vitro study
- 25 Downloads
The effects of epigallocatechin-3-gallate (EGCG) and metformin single treatment have been tested against hepatocellular carcinoma (HCC). This study aimed to assess the combination effects of EGCG and metformin on proliferation and apoptosis of HepG2cells and identified new potential molecular targets. The effect of EGCG and metformin against cell proliferation in HepG2 was determined using MTT assay. Reverse transcription polymerase chain reaction was applied to examine the gene expression of cyclin D1, lncRNA-AF085935, caspase-3, survivin and VEGF. The level of protein expression of glypican-3 was assessed by western blot. In HepG2 cells, EGCG and metformin combination treatment exhibited high significant effect against tumor proliferation. It significantly reduced cyclin D1, lncRNA-AF085935, glypican-3 and promoted apoptosis through increasing caspase3 and decreasing survivin compared to control cells. Moreover, EGCG and metformin treated cells showed decreased expression levels of VEGF. Our study provided new insights of the anticarcinogenic effects of EGCG and metformin on HCC through their effects on glypican-3 and lncRNA-AF085935.
KeywordsHepatocellular carcinoma EGCG Metformin Glypican-3 LncRNA-AF085935
Compliance with Ethical Standards
Conflict of interest
All authors declared that there was no conflict of interest.
- 8.Ma SJ, Zheng YX, Zhou PC, Xiao YN, Tan HZ (2016) Metformin use improves survival of diabetic liver cancer patients: systematic review and meta analysis. Oncotarget 7(40):66202–66211Google Scholar
- 18.Li S, Wu L, Jiao F, Li J, Liu T, Rong Z, Shizan X, Keran C, Yuqing Z, Shunfeng Z, Rui K, Kan C, Fan W, Yujing X, Lu J, Yingqun Z, Weiqi D, Chuanyong G (2016) In vitro and in vivo study of epigallocatechin-3-gallate-induced apoptosis in aerobic glycolytic hepatocellular carcinoma cells involving inhibition of phosphofructokinase activity. Sci Rep 6:28479CrossRefGoogle Scholar
- 19.Kuo PL, Lin CC (2003) Green tea constituent (–)-epigallocatechin-3- gallate inhibits Hep G2 cell proliferation and induces apoptosis through p53-dependent and Fas-mediated pathways. J Biomed Sci 10:219–227Google Scholar
- 25.Cai X, Hu X, Cai B, Wang Q, Li Y, Tan X, Hu H, Chen X, Huang J, Cheng J, Jing X (2013) Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo. Oncol Rep 30:2449–2457CrossRefGoogle Scholar
- 29.Xiao-ting Z, Ji-hang Y, Teng-teng Z, Yang-yang L and Xiao-yang C. (2016) Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3. FEBS J. 283:3739–3754Google Scholar
- 32.Zittermann SI, Capurro MI, Shi W, Filmus J (2010) Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer 126:1291–1301Google Scholar
- 47.Shirakami Y, Shimizu M, Adachi S (2009) (–)-Epigallocate-chin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. Cancer Sci 100:1957–1962. [PubMed: 19558547]CrossRefGoogle Scholar